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To better understand the pathophysiology of B cell populations—the precursors of antibody secreting
cells—during chronic human immunodeﬁciency virus (HIV) infection, we examined the phenotype of
circulating B cells in newly diagnosed Africans. We found that all African individuals displayed low
levels of naive B cells and of memory-type CD27
þ B cells, and high levels of differentiated B cells. On
the other hand, HIV-infected African patients had a population of germinal center B cells (i.e. CD20
þ,
sIgM
2, sIgD
þ, CD77
þ, CD138
^), which are generally restricted to lymph nodes and do not circulate
unless the lymph node architecture is altered. The ﬁrst observations could be linked to the tropical
environment whereas the presence of germinal center B cells may be attributable to chronic exposure to
HIV as it is not observed in HIV-negative African controls and HAART treated HIV-infected
Europeans. It may impact the management of HIV infection in countries with limited access to HIV
drugs and urges consideration for implementation of therapeutic vaccines.
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INTRODUCTION
The human immunodeﬁciency virus (HIV) induces
profound disturbances in cellular and humoral immunity,
both at the speciﬁc and non-speciﬁc levels (Fauci et al.,
1996). Typically, untreated HIV-infected individuals
experiencediseaseprogressionandmanifesthypergamma-
globulinemia with antibodies (Abs) to core and
surface components of HIV, but lack speciﬁc neutralizing
anti-HIV envelop Abs and speciﬁc recall Abs to
naturally encountered or vaccine delivered antigens (Ag)
(Amadori and Chieco-Bianchi, 1990). A classic feature of
HIV-disease progression is the consistent destruction of
lymph nodes (LN) contributing to the progressive loss of
the CD4
þ T-cell compartment—the hallmark of HIV
infection and AIDS (Richard et al., 2002).
Management of HIV-infected individuals in Africa—
and particularly in poor countries—represents a real
challenge. Few strategies are in place in tropical Africa,
and while the introduction of antiretroviral drugs is
planned, only vaccination strategies can truly represent a
chance to limit infection spreading (Marcus et al., 2002).
Whether these vaccines are expected to be preventive or
therapeutic, their ultimate goal is to limit viral replication
to favor the expansion of speciﬁc cytolytic T cells (CTLs)
and induce B cells to produce neutralizing Abs (Peters,
2001). These strategies may be reinforced with the help of
an intact innate immune system (Siegal and Spear, 2001).
In the present study, we characterized the peripheral B
cell compartment of 15 drug-naive HIV-infected individ-
uals. At homeostasis or in disease states that do not affect
LN architecture or bone marrow production, blood B cells
are comprised of naive and non-naive (mostly memory) B
lymphocytes which recirculate, especially after antigenic
exposure. These B cells represent a milestone of the
speciﬁc infection they defend against as they differentiate
into (neutralizing) Ab-secreting cells and, therefore are
targets of vaccination strategies. Indeed, the presence of
circulating cells assumed to be plasmocytes—capable of
secreting anti-HIV Abs—has been reported in HIV
þ
patients; these studies examined treated Americans or
untreated, Europeans with low viral load, respectively
(Marcus et al., 2002; Richard et al., 2002). In the present
work, we studied a group of HIV-infected individuals
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germinal center (GC) originating-B lymphocytes (not
plasmocytes) circulating in the periphery. This obser-
vation may impact future vaccination strategies.
MATERIALS AND METHODS
Patients
African donors were consultants at the “Ho ˆpital Commu-
nautaire” of Bangui, Central African Republic (CAR) as
spouses of hospitalized patients with AIDS. The
prevalence of HIV-infection in CAR is estimated to be
12.9% of the adult population (UNAIDS/WHO 2002). All
donors enrolled in this study were informed and consented
to donate blood for research purposes, according to the
rules of the ad hoc Ethics Committee set up by the Institut
Pasteur in Bangui, in the absence of a National Ethics
Committee. None of the blood donors were previously
diagnosed with HIV infection, and all were indeed
antiretroviral drug-naive. Patients were selected on the
basis of African AIDS symptoms deﬁned by the WHO at
Bangui in 1985 (Diagnosing symptomatic HIV infection
and AIDS in adults, 1993). Approximately 10ml of
heparinized blood was obtained from a series of
individuals and 15 were diagnosed HIV
þ. HIV serology
was routinely followed in Bangui using the Vironostika
HIV-Uniform II plus O test (Organon Teknika, Durham,
NC). Plasma viral load (VL), determined in Saint-Etienne
using a nested PCR technique as previously described
(Peters, 2001), ranged from 10,000 to 80,000copies/ml.
HIV-1 clades A predominate in Bangui (Muller-Trutwin
et al., 1999). Matched controls consisted of 9 HIV-
negative patients African PBMC samples.
In order to compare certain biological parameters, the
phenotype of blood B cells from Europeanvolunteer blood
donors was also tested in this survey. Informed consent
was obtained from the European patients according to
the requirements of the National French Ethics. There
were 30 HIV
þ European blood donors followed by the
Department of Infectious Diseases at the University
Hospital in Saint Etienne, France. Approximately 10ml of
heparinized blood was obtained speciﬁcally for the
present study. All patients enrolled in this study were
treated with antiretroviral drugs according to current
protocols and were monitored for clinical and biological
parameters for disease progression. Plasma VL was
routinely monitored in patients over time. At the time of
sampling for the present work, 28/30 patients had VL of
less than 50copies/ml. Matched controls consisted of 9
HIV-negative patients European PBMC samples.
T and B Cell Phenotyping
Standard T (CD4
þ) cell phenotyping was performed
extemporarily at the Institut Pasteur in Bangui. Lympho-
cyte subsets were analyzed on a FACSCalibur ﬂow
cytometer (Becton Dickinson Immunocytometry
Systems, San Jose, CA) with two monoclonal antibodies
(MAbs) (aCD4–aCD8, Becton Dickinson Immuno-
cytometry Systems).
The extended B cell phenotyping was performed in
Saint-Etienne. PBMCs, stored in Stabilcytee (BioErgo-
nomics, St Paul, MN) in Africa, were stained with the
following mAbs conjugated with ﬂuorescein isothio-
cyanate (FITC), phycoerythrin (PE) or RPE-Cy5
suitable for three-color ﬂow cytometry. The following
markers were used: CD20-RPECy5, IgD-FITC, IgM-PE,
CD38-FITC, CD38-PE, CD27-PE (all from DAKO,
Copenhaguen, Denmark); CD77-FITC (BD-Pharmingen,
San Diego, CA); CD138-PE (Coulter-Immunotech,
Marseille, France). Ig isotype-matched FITC-, PE- and
RPECy5-conjugated mouse Ab (DAKO) were used as
negative controls to test for non-speciﬁc staining. Brieﬂy,
0.5 £ 10
6 cells were stained with the appropriate mAb for
45min on ice. Afterwards, the cells were washed in PBS
with 10% fetal calf serum and ﬁxed in PBS containing 4%
paraformaldehyde. Flow cytometry was performed on
the following day using a FacsVantage-SF BD and
the CellQuest-Proe software (Becton-Dickinson,
San-Jose, CA).
Statistics
Means ^ SEM of data between the blood donor groups
were compared using the Mann–Whitney test. Statistical
analysis was performed using the Statviewe software
(SAS Institute INC, Cary, NJ).
RESULTS
African Blood Donor Group
The design of the present survey, i.e. the study of blood B
cell of volunteer, HIV-infected African individuals
unaware of their infection, living with AIDS-spouses,
has considerably limited the size of this cohort. The initial
serological test performed on blood samples for each
volunteer deﬁned two groups (HIV
þ and HIV
2). Newly
recognized HIV
þ individuals were informed of their
serological status, counseled by the physician at the
hospital and entered into the speciﬁc HIV program at the
clinics. The mean CD4
þ T cell count ^ SEM was
316.6 ^ 65.6cells/ml for the 15 HIV
þ individuals and
913 ^ 66cells/mlf o rt h e1 1H I V
2 individuals;
P ¼ 0.0007) (Table I). As very few of the recently
diagnosed patients were hospitalized (except #6 and #8)
for various reasons (including economical), we were
unable to perform CDC staging.
Major Characteristic of Circulating B Cells in HIV-
infected African Blood Donors
The HIV
þ African blood donors presented lower B cell
counts than the HIV
2Africans. The % mean of CD20
þ B
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þ
individuals and 6.7 ^ 0.6 for the 9 HIV
2 individuals;
P ¼ 0.1.
A careful examination of the B cell subpopulation
phenotype was then carried out by 3 color-ﬂow cytometry.
We ﬁrst determined the relative proportions of naive and
non-naive circulating blood B cells on the basis of their
reactivity with anti-CD20 and anti-IgM ^ anti-IgD
ﬂuorescent-dye labeled Abs. As shown in Fig. 1,
CD20
þ, surface-(s)IgM
þ/sIgD
þ cells assumed to be
naive B cells (Banchereau and Rousset, 1992) were nearly
equivalent in HIV
þ than in HIV
2 blood donors (28 ^ 4.6
vs. 20.4 ^ 4.3%, respectively). The HIV
þ blood donors
also displayed approximately equal CD20
þ, sIgM
^,
sIgD
2 differentiated B cells (61.1 ^ 4.6 vs.
67.1 ^ 7.9%, respectively). In contrast, CD20
þ sIgD
þ
sIgM
2 germinal center (GC)-type B cells were signiﬁ-
cantly higher in HIV
þ compared to HIV
2 patients
(11.9 ^ 2 vs. 5.2 ^ 0.6%; P ¼ 0.03). In total, 8/15 (53%)
African HIV
þ donors displayed $10% of GC-type
CD20
þ B cells.
To further document these ﬁndings, and to ascribe
potential functions to the non-naive blood B cells in HIV
þ
donors, we tested the CD20
þ B cells for reactivity with
mAbs to CD27 (characterizing circulating memory-type
blood B cells), CD77 (characterizing GC-type B cells),
CD138 (characterizing post-GC B cells) and anti-CD38
(characterizing pre-plasmocytes and plasmocytes, and
certain activated B cells). African HIV
þ blood donors
displayed similar levels of CD20
þ CD27
þ memory-type
blood B cells compared with their non-infected counter-
parts (Fig. 2A). However, there were signiﬁcantly more
CD20
þ CD77
þ GC-type B cells (9.7 ^ 1.8 vs.
3.2 ^ 0.7%; P ¼ 0.006) compared to HIV
2 Africans.
Of note, although this cannot be compared stricto sensu,
unexpected proportions of CD20
þ CD138
þ post-GC B
cells were found in HIV
þ and HIV
2 Africans compared to
as in Europeans (Fig. 2A,B). Moreover, HIV
þ and HIV
2
African donors had fewer CD20
þ, sIgD
þ, sIgM
þ naive B
cells (28.1 ^ 4.6 and 20.4 ^ 4.3%, respectively) com-
pared to HIV
þ and HIV
2 European individuals (72.2 ^ 3
and 73 ^ 2.2%, respectively). African donors also had
more CD20
þ,s I g M
^,s I g D
2 differentiated B cells
(61.1 ^ 4.6 vs. 23.5 ^ 1.9%) and considerably more
CD20
þ sIgD
þ sIgM
2 CG-type B cells compared to
European patients (HIV
þ: 11.9 ^ 2 vs. 3.2 ^ 0.7; HIV
2:
5.2 ^ 0.6 vs. 3.2 ^ 0.7, respectively). Moreover,
HIV-infected or uninfected, all African individuals
FIGURE 1 Blood B cell phenotype in HIV
þAfrican donors. The bar diagrams show the differential proportion of naive, differentiated and centro-
germinative B cells in the periphery (i.e. blood circulating) of HIV-infected, untreated Africans. CD20
þ, sIgM
þ sIgD
þ cells are naiveB cells (gray bars);
CD20
þ sIgM
^, sIgD
2 cells are differentiated B cells (white bars); and CD20
þ, sIgM
2 sIgD
þ cells are centro-germinative B cells (black bars).
The analysis shows data obtained with blood from 15 HIV-1 infected patients and 9 HIV-negative patients.
TABLE I Major characteristics of the HIV
þAfrican patients enrolled in
the study
Age CD4 VL B cells
1 M 38 163 5.5 7
2 M 19 510 4 5.5
3 M 43 123 5.9 3
4 F 25 ND ND 5
5 M 39 456 5.4 3.2
6 F 28 128 5.9 4.2
7 F 25 956 4.26 2
8 M 47 5 5.1 2
9 M 22 ND ND 9
10 M 34 ND 4.46 7
11 M 52 13 5 1
12 F 45 181 ND 6
13 F 31 203 4.15 3
14 F 32 745 4.04 7
15 F 30 ND 5.2 9
M and F stand for Male and Female; Age is expressed in years; CD4 count is
expressed in CD4
þcells/ml; plasma viral load is expressed in log(copies/ml); B cell
is the % of CD20
þ cells within PBMC. ND stands for Not determined.
GERMINAL CENTER B CELLS IDENTIFICATION IN AIDS 25displayed at least ﬁve fold fewer memory-type CD27
þ B
cells (4.9–5 vs. 24.1–38.4%) than Europeans while HIV
þ
infected Europeans had signiﬁcantly less CD20
þ CD27
þ
memory-type B blood B cells than their non-infected
counterparts (P ¼ 0.01; Fig. 2B).
DISCUSSION
In this study, we attempted to integrate observations on
circulating B lymphocytes in HIV-infected drug-naive
individuals. We tried to understand to what extent, and
how, the B cell compartment, is affected by HIV-infection,
especially in drug-naive patients which represent the
majority of infected individuals worldwide. The next step
would be to try to circumvent the B cell disorders and in so
doing protect the B cell compartment to allow the
development of protective-type Abs, awaiting an anti-
disease vaccine.
The study population consisted of African individuals
unique in four areas: (i) origin and genetic background;
(ii) hyperactivation of the immune system by numerous
infectiouspathogensleadingtotheso-calledtropicalAIDS
(Germani etal.,1998;Bentwichetal.,2000;Begaud etal.,
2003); (iii) no access to antiretroviral treatment and
insufﬁcient access to health care and (iv) virus clade.
This and other studies have shown that HIV infection
leads to profound alterations at the level of B cell
homeostasis (Richard et al., 2002). Although exacerbated
plasmacytosis in bone marrow and in peripheral tissues
have been consistently reported in HIV infection (Calenda
and Chermann, 1992; Nagase et al., 2001), no consensus
has been reached on whether plasmocytes can circulate.
We did not ﬁnd circulating plasmocytes in our close
examination of blood smears (data not shown). However,
we found a fraction of circulating B lymphocytes
phenotypically modiﬁed when compared to HIV-unin-
fected individuals, such as the reduction in CD27
þ
memory-type B cells (De Milito et al., 2001). Certain
studies aimed at characterizing the Ab secreting cell
precursors found various phenotypic changes such as the
low expression of CD21 (Moir et al., 2001), CD23
(Rodriguez et al., 1996), CD38, CD39, CD20, CD37,
CD71 (Fournier et al., 2002) and modiﬁed expression of
CD22, sIgM and sIgG molecules (Dawood et al., 1998)
etc, suggesting that these cells could be early plasma cells
originating from GCs (Forster et al., 1997). Our study
showed that African individuals had fewer naive
(CD20
þ/sIgM
þ/sIgD
þ) and memory-type (CD20
þ/
CD27
þ ^ sIgD
2 sIgM
^) B cells compared to European
individuals. This could be linked to the tropical
environment where, for example, chronic parasite
infections are known to affect the immune system.
Multiparasitisme is indeed frequently observed in CAR
(Begaud et al., 2003). On the other hand, we found
signiﬁcantly more CD20
þ/CD77
þ B cells (CD77 being a
phenotypic characteristic of centroblasts (Wiels, 2000))
in HIV
þ Africans compared to HIV-uninfected individ-
uals or European patients. This second particularity seems
to be directly associated with the evolution of HIV
infection in African individuals and with the presence of
the virus (high VL) in the absence of treatment. We also
found elevated numbers of B cells expressing surface
CD138 (a feature of post-GC B cells) (Wijdenes et al.,
1996). However, CD138 marker is imprecisely known,
rendering this staining difﬁcult to interpret. Taken
together, our ﬁndings strongly suggest that the unexpected
circulating B cells share the features of GC- (Bm3s and
Bm3) and post-GC-B cells (Liu et al., 1996). Invivo, such
lymphocytes may have received progression and differ-
entiation signals and/or may be pre-switched. They may
differentiate terminally in bone marrow and in tissue-as-
sociated lymphoid organs, and some may possibly be
aberrantly located as a result of HIV-infection (Forster
et al., 1997). It is not clear, however, that these GC cell
subsets differentiate in vivo and in vitro (our unpublished
observations) as we have not yet speciﬁcally identiﬁed a
population ascribed to a centrocytic phenotype.
FIGURE 2 Differential expression of CD77, CD138 and CD27 markers on circulating CD20
þ B cells. (A) African blood donors; (B) European blood
donors; Black bars, HIV-infected individuals; Gray bars, HIV-uninfected individuals.
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disturbance of the LN in HIV-infection, AIDS and
HIV-associated Hodgkin and non-Hodgkin lymphomas
(Clarke and Glaser, 2001). Further, it has been reported
that disruption of GCs blocks the formation of B cell
memory (Roy et al., 2002) which ﬁts with the present
observation. Our study may also suggest that the
hypergammaglobulinemia observed during HIV-infection
at least partly reﬂects the disorganization of LNs and
particularly GCs, which may prematurely release into the
periphery GC- and post-GC-B lymphocytes poised to
differentiate terminally. Our study differs from other
studies in that we have enrolled African patients who were
heavily infected with HIV. Our observations focused on
the direct relationship between peripheral B cell subset
imbalances and LN disorganization, and the absence of
treatment (and the absence of viral control). The
architectural disorganization of the LN—along with the
aberrant release of early plamocytes by the bone
marrow—seems largely responsible for the B cell
dysregulation observed during HIV-infection progression
in African countries. This strongly argues for the
establishment of therapeutic vaccines trials as we await
the implementation of drug treatment programs.
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